Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.

Waterhouse DN, Sutherland BW, Santos ND, Masin D, Osooly M, Strutt D, Ostlund C, Anantha M, Harasym N, Manisali I, Wehbe M, Bally MB, Webb MS.

Invest New Drugs. 2014 Dec;32(6):1071-82. doi: 10.1007/s10637-014-0138-x. Epub 2014 Jul 27.

2.

Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.

Hare JI, Neijzen RW, Anantha M, Dos Santos N, Harasym N, Webb MS, Allen TM, Bally MB, Waterhouse DN.

PLoS One. 2013 Apr 23;8(4):e62349. doi: 10.1371/journal.pone.0062349. Print 2013.

3.

Nanotheraputics.

Ravi Kumar MN, Blanco-Prieto MJ, Waterhouse DN.

Cancer Lett. 2013 Jul 1;334(2):155-6. doi: 10.1016/j.canlet.2013.02.047. Epub 2013 Mar 21. No abstract available.

PMID:
23523611
4.

Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.

Waterhouse DN, Yapp D, Verreault M, Anantha M, Sutherland B, Bally MB.

Nanomedicine (Lond). 2011 Nov;6(9):1645-54. doi: 10.2217/nnm.11.140.

PMID:
22077466
5.

Retraction. A novel combination of Chinese medicines to treat advanced cancers and lymphomas tested in rats.

Waterhouse DN.

Chin Med. 2010 Mar 16;5:10. doi: 10.1186/1749-8546-5-10. No abstract available.

6.

A novel combination of Chinese medicines to treat advanced cancers and lymphomas in rats.

Waterhouse DN.

Chin Med. 2009 Nov 27;4:22. doi: 10.1186/1749-8546-4-22. No abstract available. Retraction in: Chin Med. 2010 Mar 16;5:10.

7.

Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK).

Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S, Bally MB.

Mol Cancer Ther. 2008 Jan;7(1):59-70. doi: 10.1158/1535-7163.MCT-07-0329.

8.

Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy.

Waterhouse DN, Bally MB.

Nanomedicine (Lond). 2006 Oct;1(3):359-63. No abstract available.

PMID:
17716167
9.

Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs.

Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB.

Mol Cancer Ther. 2007 Mar;6(3):844-55. Epub 2007 Mar 5.

10.

Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers.

Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB.

Curr Cancer Drug Targets. 2006 Sep;6(6):455-89. Review. Erratum in: Curr Cancer Drug Targets. 2006 Dec;6(8):753. Zhang, YZ [corrected to Wang, YZ].

PMID:
17017873
11.

Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels.

Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB.

Pharm Res. 2005 Jun;22(6):915-22. Epub 2005 Jun 8.

PMID:
15948035
12.

The liposomal formulation of doxorubicin.

Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB.

Methods Enzymol. 2005;391:71-97.

PMID:
15721375
13.

Preparation, characterization, and biological analysis of liposomal formulations of vincristine.

Waterhouse DN, Madden TD, Cullis PR, Bally MB, Mayer LD, Webb MS.

Methods Enzymol. 2005;391:40-57.

PMID:
15721373
14.

HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.

Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB.

Mol Cancer Res. 2004 Nov;2(11):606-19.

15.

Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model.

Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB.

Cancer Biol Ther. 2004 Feb;3(2):197-204. Epub 2004 Feb 1.

PMID:
14726684
16.
17.

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.

Waterhouse DN, Tardi PG, Mayer LD, Bally MB.

Drug Saf. 2001;24(12):903-20. Review.

PMID:
11735647
18.

Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs.

Waterhouse DN, Dos Santos N, Mayer LD, Bally MB.

Pharm Res. 2001 Sep;18(9):1331-5. No abstract available.

PMID:
11683249

Supplemental Content

Loading ...
Support Center